IMPROVE-IT clinical implications. Should the "high-intensity cholesterol-lowering therapy" strategy replace the "high-intensity statin therapy"?

Atherosclerosis

Volumn 240, Issue 1, 2015, Pages 161-162

  Masana, Luis ^a   Pedro Botet, Juan ^b   Civeira, Fernando ^c  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

Ezetimibe; High intensity cholesterol lowering therapy; IMPROVE IT

Indexed keywords

ATORVASTATIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; BIOLOGICAL MARKER; CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG THERAPY; HIGH INTENSITY CHOLESTEROL LOWERING THERAPY; HIGH INTENSITY STATIN THERAPY; HUMAN; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; DOWN REGULATION; DRUG COMBINATION; EVIDENCE BASED MEDICINE; HYPERCHOLESTEROLEMIA; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; BIOMARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL; CLINICAL TRIALS AS TOPIC; DOWN-REGULATION; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; EZETIMIBE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84928314579     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.03.002     Document Type: Note

References (13)

1. Cannon, CP on behalf of the IMPROVE IT investigators IMPROVE-IT trial: a comparison of Ezetimibe/Simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. 2014 late-breaking clinical trial abstracts. Circulation 2014, 130:2105-2126.
2. Steinberg D. In celebration of the 100th anniversary of the lipid hypothesis of atherosclerosis. J.Lipid Res. 2013, 54:2946-2949.
3. Cannon C.P., Giugliano R.P., Blazing M.A., Harrington R.A., Peterson J.L., Sisk C.M., Strony J., Musliner T.A., McCabe C.H., Veltri E., Braunwald E., Califf R.M. IMPROVE-IT Investigators. Rationale and design of IMPROVE-IT (IMProved reduction of outcomes: vytorin efficacy international trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am. Heart J. 2008, 156:826-832.
4. Laufs U., Descamps O.S., Catapano A.L., Packard C.J. Understanding IMPROVE-IT and the cardinal role of LDL-C lowering in CVD prevention. Eur. Heart J. 2014, 35:1996-2000.
5. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C., Bhala N., Peto R., Barnes E.H., Keech A., Simes J., Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681.
6. Davidson M.H. Clinical significance of statin pleiotropic effects: hypotheses versus evidence. Circulation 2005, 111:2280-2281. Erratum in Circulation. 2005;112:e126.
7. Koren M.J., Giugliano R.P., Raal F.J., Sullivan D., Bolognese M., Langslet G., Civeira F., Somaratne R., Nelson P., Liu T., Scott R., Wasserman S.M., Sabatine M.S. OSLER Investigators. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label study of Long-Term evaluation against LDL-C (OSLER) randomized trial. Circulation 2014, 129:234-243.
8. Expert Panel on Detection Evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA 2001, 285:2486-2497.
9. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z., Catapano A.L., De Backer G., Graham I., Taskinen M.R., Wiklund O., Agewall S., Alegria E., Chapman M.J., Durrington P., Erdine S., Halcox J., Hobbs R., Kjekshus J., Filardi P.P., Riccardi G., Storey R.F., Wood D. ESC committee for practice guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 2011, 32:1769-1818.
10. Gielen S., Landmesser U. The year in cardiology 2013: cardiovascular disease prevention. Eur. Heart J. 2014, 35:307-312.
11. Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members An international atherosclerosis society position paper: global recommendations for the management of dyslipidemia-full report. J.Clin. Lipidol. 2014, 8:29-60.
12. Stone N.J., Robinson J.G., Lichtenstein A.H., Bairey Merz C.N., Blum C.B., Eckel R.H., Goldberg A.C., Gordon D., Levy D., Lloyd-Jones D.M., McBride P., Schwartz J.S., Shero S.T., Smith S.C., Watson K., Wilson P.W. American College of Cardiology/American Heart association task force on practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart association task force on practice Guidelines. J.Am. Coll. Cardiol. 2014, 63:2889-2934. Erratum in: J Am Coll Cardiol 2014;63:3024-3025.
13. Sattar N.A., Ginsberg H., Ray K., Chapman M.J., Arca M., Averna M., Betteridge D.J., Bhatnagar D., Bilianou E., Carmena R., Ceška R., Corsini A., Erbel R., Flynn P.D., Garcia-Moll X., Gumprecht J., Ishibashi S., Jambart S., Kastelein J.J., Maher V., Marques da Silva P., Masana L., Odawara M., Pedersen T.R., Rotella C.M., Salti I., Teramoto T., Tokgozoglu L., Toth P.P., Valensi P., Vergès B. The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. Atheroscler. Suppl. 2014, 15:1-15.